Breaking the oncogenic alliance: advances in disrupting the MTDH–SND1 complex for cancer therapy

Noha A. Ahmed; Ahmed A. Allam; Hassan A. Rudayni; Faris F. Aba Alkhayl; Al Mokhtar Lamsabhi; Emadeldin M. Kamel

doi:10.1039/d5ra04310g

January 1, 2025RSC AdvancesOpen Access

Breaking the oncogenic alliance: advances in disrupting the MTDH–SND1 complex for cancer therapy

View Full Paper

Ask AI

Bookmark

Share

Key Points

Disrupting the MTDH–SND1 complex enhances antitumor effects in cancer models, effectively reducing cancer growth.
Key findings show that peptide and small-molecule inhibitors trigger SND1 degradation and halt oncogenic signaling pathways.
This preclinical analysis examines therapeutic strategies involving complex disruption for improved cancer outcomes.
Results highlight the potential of targeting MTDH–SND1 as a promising approach for cancer therapies, suggesting new treatment avenues.

Implication

Experimental therapy disrupts the MTDH–SND1 complex, suppressing oncogenic pathways, indicating potential for cancer treatment.

Abstract

Disruption of the MTDH–SND1 complex using peptide or small-molecule inhibitors triggers SND1 degradation, suppresses oncogenic signaling pathways, and produces potent antitumor effects in preclinical cancer models.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ahmed et al. (2025) studied this question.

synapsesocial.com/papers/68af63e9ad7bf08b1eae48af https://doi.org/10.1039/d5ra04310g

View Full Paper

Ask AI

Bookmark

Share

Breaking the oncogenic alliance: advances in disrupting the MTDH–SND1 complex for cancer therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Breaking the oncogenic alliance: advances in disrupting the MTDH–SND1 complex for cancer therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading